Soft tissue injuries keep climbing as people stay active later in life, and the same orthopedic soft tissue repair companies lead the market year after year. According to iData Research, the global market topped $5 billion in 2025 and is forecast to reach $7.3 billion at a 5.3% CAGR. This guide ranks each company, explains why it leads, and covers product and deal activity from the past year.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Who are the top orthopedic soft tissue repair companies in 2026
➜ Why Arthrex leads the orthopedic soft tissue repair market
➜ What makes Smith & Nephew a top soft tissue repair company
➜ Why DePuy Synthes ranks among the top soft tissue repair companies
➜ How Stryker competes in the orthopedic soft tissue repair market
➜ What is driving the orthopedic soft tissue repair market in 2026
➜ Frequently asked questions about orthopedic soft tissue repair companies
Key Takeaways
- Arthrex is the clear market leader, ranking first in six of the seven device segments tracked by iData Research.
- Smith & Nephew, DePuy Synthes, and Stryker round out the top four.
- The global market is worth more than $5 billion in 2025 and is projected to reach $7.3 billion by 2032.
- Rotator cuff repair is the largest segment, while hip arthroscopy is the fastest growing.
- Biologic healing and robotics are the two biggest innovation themes shaping the 2026 landscape.
Who are the top orthopedic soft tissue repair companies in 2026
The four leading orthopedic soft tissue repair companies in 2026 are Arthrex, Smith & Nephew, DePuy Synthes, and Stryker.
This ranking is based on iData Research market share data across seven segments.
Those segments are Achilles tendon repair, rotator cuff repair, shoulder labrum repair, biceps tenodesis, ACL/PCL reconstruction, meniscal repair, and hip arthroscopy.
Arthrex holds first place in six of the seven.
Smith & Nephew leads meniscal repair and places second or third almost everywhere else.
DePuy Synthes and Stryker fill the remaining top positions.
For a closer look at how these leaders split the market, see iData’s analysis of the three leading sports medicine companies.
Why Arthrex leads the orthopedic soft tissue repair market
Arthrex is the top orthopedic soft tissue repair company because of the breadth of its implant portfolio.
It ranks first in Achilles tendon, rotator cuff, shoulder labrum, biceps tenodesis, ACL/PCL, and hip arthroscopy.
In the shoulder, its SpeedBridge construct pairs FiberTak RC soft anchors with the SwiveLock knotless fixation system.
For tough revision repairs, the CuffMend system adds a dermal allograft to reinforce the tendon.
On the knee side, the TightRope button system anchors its ACL line, and the newer TightRope SB removes metal hardware entirely.
For meniscal work, the ZoneNavigator system delivers SutureTape with single-handed control.
This depth across every joint is what keeps Arthrex ahead of the field.
What makes Smith & Nephew a top soft tissue repair company
Smith & Nephew built its position on biologic healing rather than hardware alone.
It leads the meniscal repair segment and holds top-three spots in shoulder, ACL/PCL, and hip procedures.
The centerpiece is the REGENETEN Bioinductive Implant, a collagen scaffold used in more than 150,000 patients.
The implant is placed in a procedure that can take under 15 minutes, then resorbs and is replaced by new tendon-like tissue within about six months.
Momentum is building behind this approach. In August 2025, the American Academy of Orthopaedic Surgeons issued a strong recommendation for the use of bioinductive implants in rotator cuff repair, a position supported by a recent systematic review of collagen implant outcomes.
In January 2026, the company also acquired Integrity Orthopaedics and its Tendon Seam rotator cuff repair system.
Why DePuy Synthes ranks among the top soft tissue repair companies
DePuy Synthes, part of Johnson & Johnson MedTech, competes through its Mitek Sports Medicine franchise.
It holds top-three market share in rotator cuff, shoulder labrum, biceps tenodesis, ACL/PCL, and meniscal repair.
In the ACL segment, the Milagro Advance interference screw uses a Biocryl Rapide biocomposite that resorbs over time and lowers the long-term foreign-body burden of metal or PEEK screws.
For the shoulder, the FASTIN RC threaded titanium anchor is designed for soft tissue reattachment.
The Cuff Link device adds support during aggressive rehabilitation after rotator cuff surgery.
A trusted surgeon-education program and a broad orthopedics platform help DePuy Synthes hold its place near the top.
How Stryker competes in the orthopedic soft tissue repair market
Stryker rounds out the top four orthopedic soft tissue repair companies.
Its strongest soft tissue positions are in Achilles tendon repair and hip arthroscopy, where it ranks second in both segments.
The company leans on its arthroscopy and sports medicine lines, backed by one of the largest orthopedic platforms in the industry.
Robotics is its clearest growth lever. In March 2026, Stryker announced the full market release of its Mako Shoulder system at the AAOS 2026 meeting.
The system lets surgeons perform humeral and glenoid preparation with greater robotic precision than manual techniques.
That robotic momentum is expected to support Stryker’s broader shoulder and joint business through the forecast period.
What is driving the orthopedic soft tissue repair market in 2026
Demand is rising from an aging but active population.
More people are staying in high-impact fitness later in life, which lifts injury rates and procedure volumes.
Minimally invasive techniques have also pulled cases away from non-surgical management.
Rotator cuff repair is the largest segment, while hip arthroscopy is the fastest growing as diagnostic tools for hip impingement improve.
ACL reconstruction volumes continue to climb alongside youth and recreational sports participation, a trend confirmed in recent ACL reconstruction trend data.
Innovation is moving fast, too. In February 2026, the FDA granted Breakthrough Device Designation to Orthonika’s Total Meniscus Replacement implant.
For related leaders in nearby markets, see iData’s orthopedic trauma companies and global spine companies.
Frequently asked questions about orthopedic soft tissue repair companies
Who is the largest orthopedic soft tissue repair company in 2026?
Arthrex is the largest. It ranks first in six of the seven device segments tracked by iData Research, including rotator cuff, ACL/PCL, and hip arthroscopy.
How big is the orthopedic soft tissue repair market?
iData Research valued the global market at over $5 billion in 2025. It is expected to grow at a 5.3% CAGR to reach $7.3 billion by 2032.
Which orthopedic soft tissue repair segment is growing fastest?
Hip arthroscopy is the fastest-growing segment, driven by better diagnostic tools for femoroacetabular impingement and a shift toward repairing the labrum rather than removing it.
What is the REGENETEN Bioinductive Implant?
It is Smith & Nephew’s collagen scaffold for rotator cuff repair. After placement, it resorbs and is replaced by new tendon-like tissue within about six months, and it has been used in more than 150,000 patients.
For full rankings, market sizing, and segment data, explore the iData Research orthopedic soft tissue repair report.
External source: Trends of Pediatric Anterior Cruciate Ligament Reconstruction Surgery in Korea: Nationwide Population-Based Study (National Library of Medicine, 2025).
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
